Q-omics provides the consensus-scored RPS20P14 profile across patient tissues and cancer cell-line models. RPS20P14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPS20P14 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RPS20P14 RNA expression shows 15,428 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where RPS20P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P14 survival associations across molecular data types. RPS20P14 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P14 RNA expression–survival associations across cancer types. High RPS20P14 expression shows unfavorable associations in UVM, LUAD and ACC, but favorable associations in THCA, CHOL and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPS20P14 RNA expression.
This table summarizes RPS20P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P14 shows higher tumor expression in COAD, KIRC, KIRP, LIHC, HNSC and CHOL. The COAD box plot shows higher RPS20P14 RNA expression in tumor versus normal tissue (log2 FC = +1.512, t-test p < 0.001).
This table shows molecular features associated with RPS20P14 in patient tissues and cancer cell lines. In patient samples, RPS20P14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
